10:27 AM EST - Medicenna Therapeutics Corp. : Has completed enrollment in its global Phase 1/2 ABILITY-1 study of MDNA11. The Company will host a live key opinion leaders (KOL) webinar on November 10, from 9:00 a.m. to 10:00 a.m. Eastern Standard Time, to discuss updated data from the study. Medicenna Therapeutics Corp.
shares T.MDNA are trading unchanged at $0.42.
